BBIO vs. CAH

Last updated Jun 4, 2026

BBIO (BridgeBio Pharma, Inc.) and CAH (Cardinal Health, Inc.) are both stocks. Both are in the Healthcare sector — BBIO in Biotechnology, CAH in Medical Distribution. Over the past 5 years, BBIO returned 2.47%/yr vs 31.19%/yr for CAH. At a 0.12 correlation, their price movements are largely independent.

Performance

BBIO vs. CAH - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in BridgeBio Pharma, Inc. (BBIO) and Cardinal Health, Inc. (CAH). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, BBIO achieves a -14.39% return, which is significantly lower than CAH's -4.23% return.

BBIO

• 1D: 2.50%
• 1M: -5.09%
• YTD: -14.39%
• 6M: -11.69%
• 1Y: 74.52%
• 3Y*: 66.21%
• 5Y*: 2.47%
• 10Y*: —

CAH

• 1D: 0.50%
• 1M: -0.61%
• YTD: -4.23%
• 6M: -1.45%
• 1Y: 27.38%
• 3Y*: 34.49%
• 5Y*: 31.19%
• 10Y*: 12.53%

*Multi-year figures are annualized to reflect compound growth (CAGR)

BBIO vs. CAH - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019
BBIO BridgeBio Pharma, Inc.	-14.39%	178.75%	-32.03%	429.79%	-54.32%	-76.54%	102.88%	27.22%
CAH Cardinal Health, Inc.	-4.23%	76.25%	19.01%	34.15%	54.08%	-0.40%	10.09%	11.83%

Correlation

The correlation between BBIO and CAH is 0.06, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.06
Correlation (3Y) Calculated over the trailing 3-year period	0.09
Correlation (5Y) Calculated over the trailing 5-year period	0.10
Correlation (All Time) Calculated using the full available price history since Jun 28, 2019	0.12

Fundamentals

Market Cap BBIO : $12.75B CAH : $46.22B
EPS BBIO : -$3.76 CAH : $6.55
PS Ratio BBIO : 22.36 CAH : 0.19
Total Revenue (TTM) BBIO : $566.04M CAH : $250.55B
Gross Profit (TTM) BBIO : $538.20M CAH : $9.23B
EBITDA (TTM) BBIO : -$602.24M CAH : $2.79B

Return for Risk

BBIO vs. CAH — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BBIO

BBIO Risk / Return Rank: 82
BBIO Sharpe Ratio Rank: 83
BBIO Sortino Ratio Rank: 79
BBIO Omega Ratio Rank: 79
BBIO Calmar Ratio Rank: 86
BBIO Martin Ratio Rank: 86

CAH

CAH Risk / Return Rank: 68
CAH Sharpe Ratio Rank: 69
CAH Sortino Ratio Rank: 68
CAH Omega Ratio Rank: 68
CAH Calmar Ratio Rank: 66
CAH Martin Ratio Rank: 69

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

BBIO vs. CAH - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for BridgeBio Pharma, Inc. (BBIO) and Cardinal Health, Inc. (CAH). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	BBIO	CAH	Difference
Sharpe ratio Return per unit of total volatility	1.61	0.92	+0.68
Sortino ratio Return per unit of downside risk	2.26	1.65	+0.62
Omega ratio Gain probability vs. loss probability	1.30	1.22	+0.08
Calmar ratio Return relative to maximum drawdown	3.70	1.35	+2.35
Martin ratio Return relative to average drawdown	9.47	3.60	+5.88
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

BBIO vs. CAH - Sharpe Ratio Comparison

The current BBIO Sharpe Ratio is 1.61, which is higher than the CAH Sharpe Ratio of 0.92. The chart below compares the historical Sharpe Ratios of BBIO and CAH, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	BBIO	CAH	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.61	0.92	+0.68
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.03	1.24	-1.22
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.43	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.16	0.56	-0.40

Drawdowns

BBIO vs. CAH - Drawdown Comparison

The maximum BBIO drawdown since its inception was -92.80%, which is greater than CAH's maximum drawdown of -61.93%. Use the drawdown chart below to compare losses from any high point for BBIO and CAH.

Drawdown Indicators

	BBIO	CAH	Difference
Max Drawdown Largest peak-to-trough decline	-92.80%	-61.93%	-30.87%
Max Drawdown (1Y) Largest decline over 1 year	-20.25%	-20.42%	+0.17%
Max Drawdown (3Y) Largest decline over 3 years	-49.08%	-20.42%	-28.66%
Max Drawdown (5Y) Largest decline over 5 years	-91.89%	-22.80%	-69.09%
Max Drawdown (10Y) Largest decline over 10 years	—	-46.13%	—
Current Drawdown Current decline from peak	-18.06%	-14.60%	-3.46%
Average Drawdown Average peak-to-trough decline	-45.85%	-15.94%	-29.91%
Ulcer Index Depth and duration of drawdowns from previous peaks	7.89%	7.63%	+0.26%

Volatility

BBIO vs. CAH - Volatility Comparison

BridgeBio Pharma, Inc. (BBIO) has a higher volatility of 11.77% compared to Cardinal Health, Inc. (CAH) at 7.39%. This indicates that BBIO's price experiences larger fluctuations and is considered to be riskier than CAH based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	BBIO	CAH	Difference
Volatility (1M) Calculated over the trailing 1-month period	11.77%	7.39%	+4.38%
Volatility (6M) Calculated over the trailing 6-month period	34.50%	19.63%	+14.87%
Volatility (1Y) Calculated over the trailing 1-year period	46.93%	29.75%	+17.18%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	86.00%	25.20%	+60.80%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	83.86%	29.21%	+54.65%

Dividends

BBIO vs. CAH - Dividend Comparison

BBIO has not paid dividends to shareholders, while CAH's dividend yield for the trailing twelve months is around 1.04%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
BBIO BridgeBio Pharma, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
CAH Cardinal Health, Inc.	1.04%	0.99%	1.28%	1.98%	2.57%	3.80%	3.62%	3.80%	4.24%	3.00%	2.41%	1.68%

Financials

BBIO vs. CAH - Profitability Comparison

The chart below illustrates the profitability comparison between BridgeBio Pharma, Inc. and Cardinal Health, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

BBIO - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, BridgeBio Pharma, Inc. reported a gross profit of 178.39M and revenue of 180.60M. Therefore, the gross margin over that period was 98.8%.

CAH - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Cardinal Health, Inc. reported a gross profit of 2.50B and revenue of 60.94B. Therefore, the gross margin over that period was 4.1%.

BBIO - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, BridgeBio Pharma, Inc. reported an operating income of -105.96M and revenue of 180.60M, resulting in an operating margin of -58.7%.

CAH - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Cardinal Health, Inc. reported an operating income of 509.00M and revenue of 60.94B, resulting in an operating margin of 0.8%.

BBIO - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, BridgeBio Pharma, Inc. reported a net income of -164.04M and revenue of 180.60M, resulting in a net margin of -90.8%.

CAH - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Cardinal Health, Inc. reported a net income of 399.00M and revenue of 60.94B, resulting in a net margin of 0.7%.

Frequently Asked Questions

Can I hold both BBIO and CAH in my portfolio?

BBIO and CAH have a correlation of 0.06, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, BBIO or CAH?

BBIO has higher volatility (11.77%) compared to CAH (7.39%). In terms of maximum drawdown, BBIO dropped -92.80% vs CAH's -61.93%.

Which has better risk-adjusted returns?

BBIO currently has the higher Sharpe Ratio (1.61 vs 0.92), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.